bursa bayan escort görükle escort
bursa escort bayan görükle escort
görükle bayan escort bayan escort bursa http://www.ontimeescorts.com http://www.tropicanx.com http://www.klicf.com elit escort elit bayan escort alanya escort antalya escort eskişehir escort mersin escort alanya escort bodrum escort havalimanı transfer
kaçak iddaa oyna kaçak bahis yap illegal iddaa siteleri illegal bahis oyna illegal bahis şirketleri bahis siteleri
porno izle porno izle sikiş izle sikiş izle porn izle hd porno izle
Nitesh Rohatgi | Fortis Memorial Research Institute
EMERGENCY
+91 76694 16402
AMBULANCE
105010

Dr. Nitesh Rohatgi

Medical Oncology, Palliative Care Physician
Senior Director

Dr. Nitesh Rohatgi is Senior Director Medical Oncology at Fortis Healthcare, who was previously working at Max healthcare Saket and before that at the prestigious London Oncology Clinic, Harley Street, London. He is a fellow of the Royal College of Physicians (U.K Edinburgh) as well as Royal Society of medicine. Besides being a key opinion leader in Oncology in India he has been a Plon clinical trials (recently for BIRAC-Oncology) and has much publication to his name. He was trained in medical oncology, palliative medicine and teenage young adult's cancers in United Kingdom, completing his CCT in 2009. 

He was leading the Breast Medical oncology team at the Mid-Yorkshire NHS trust affiliated to Leeds Teaching Hospitals, where he previously trained, working alongside the likes of Prof. Peter Selby world renowned for his work in psycho oncology and Renal cell cancer. He then spent a couple of years at the London Oncology Clinic, Harley street in London where he worked with Dr Peter Harper and other consultants to help understand and expand the patient-centric oncology model.

He was invited as a visiting physician to the MD Anderson Cancer center, USA to share his deep understanding of cancer patient's psychology and what affects their QOL.

His work beckoned him to return to India in 2012. Since then, he has worked at Max Institute of Cancer care and simultaneously has worked to try and address the question of affordability and accessibility in cancer care. There has been a clear intent of translating critical aspects of patient care from research to the "highest possible standards of clinical practice", which according to him should be the mantra of healthcare. Recently his thought projections of leveraging costs from voluminous and variable healthcare data like India to improve accessibility to basic oncology care were

Work Experience: 
  •  Director, Medical Oncology, Max Healthcare
  • Consultant Acute Oncology and Chemotherapy London Oncology Clinic (LOC, Harley Street, London)
  • Former Consultant Medical Oncology and Educationist Leeds University,
  • UK Former Visiting Oncology Physician M.D Anderson Cancer Centre, Houston, USA
Professional Memberships: 
  • FRSM (London), 
  • MRCP (London),
  • FRCP (Edin.) 

 

Speciality Interests: 
  • Breast Cancer
  • Lung cancer
  • Gynecological Cancer
  • Gastrointestinal and Hepatobiliary cancers
  • Brain Tumors
  • Head and Neck Cancers
  • Kidney Bladder and Prostate cancers
Research Experience : 

Several Papers published in various journals the key one include:

  1. Thanyanan Reungwetwattana, Nitesh Rohatgi, Tony S. Mok & Kumar Prabhash (2021) Dacomitinib as firstline treatment for EGFR mutation-positive non-small cell lung cancer, Expert Review of Precision Medicine and Drug Development, DOI: 10.1080/23808993.2021.1909420
  2. Genomic testing in early breast cancer (EBC) for low middle income countries (LMIC): Is it worth the cost? G Shrivastav, D Arya, A Chaturvedi, C Garg, S Jain, S Mukhiya, N Rohatgi Journal of  Clinical Oncology 38 (15_suppl), e12521-e125212020
  3. Weekly chemotherapy instead of best supportive care alone must be considered for patients of small cell lung cancer with poor performance status. G Shrivastav, A Gupta, NSonthwal, SK Singla, T Mohindra, N Rohatgi. Journal of Clinical Oncology 38 (15_suppl), e21102-e211022020
  4. Genetic testing for hereditary breast and ovarian cancer in Indian population: A single institutional study. VPP Selvakumar, S Garg, J Kaur, G Kadayaprath, N Rohatgi, M Walia, Journal of Clinical Oncology 37 (15_suppl), e13153-e1315312019
  5. Clinical applicability of comprehensive genomic profiling (CGP) and assessment of tumor mutation burden (TMB): An Indian experience. A Verma, PK Julka, N Rohatgi, J Kaur Journal of Clinical Oncology 36 (15_suppl), e24210-e242102018
  6. Practical consensus recommendations on fertility preservation in patients with breast cancer J Bajpai, A Majumdar, R Satwik, N Rohatgi, V Jain, D Gupta, RAgarwal, South Asian Journal of Cancer 7 (2), 11032018
  7. Practical consensus recommendations on Her2+ ve breast cancer with solitary brain mets N Rohatgi, A Munshi, P Bajpai, M Singh, S Sahai, M Ahmad, K Singh, South Asian journal of cancer 7 (2), 11812018
  8. FoundationOne as a relevant tool for comprehensive genomic profiling and assessment of tumor mutation burden in the era of precision oncology in India. A Verma, N Rohatgi, PK Julka, M Walia, A Bahl, RS Arora, H Chaturvedi, Journal of Clinical Oncology 35 (15_suppl), e23096-e2309632017
  9. Amolecular approach to Glioblastoma Multiforme A Verma, S Gunasekar, V Goel, R Singh, RS Arora, N Rohatgi, AK Anand, International Journal 1 (1),362201 6

Presentation:

​Many across the world but key ones include

  • July 2021-Cultural, Social and Economic aspects of managing global health in a multi-polar world - from the eye of an oncologist, The policy institute, kings college London 
  •  Indian experience of BIOSIMILAR Trastuzumab at ESMO breast 2019
  •  Indian experience in patients with ROS 1 mutation
  • Clinical Trials to bedside-Role of CDK4 inhibitors
  • BRAF and NSCLC-tying the loose ends
  • Abemaciclib-not all CDK inhibitors the same
  • Atezolizumab-role in 2nd line NSCLC in palj<1%
  • Innovations in Oncology
  • Fear and belief-choices for survivorship
  • Choosing wisely-managing adenocarcinoma lung in metastatic setting
  • Roche ISPOR Educational Symposium at Tokyo
  • Will Personalized Cancer Care be the future of cancer care? ISP Malaysia
Qualification: 
MBBS DNB MNAMS M Med. (Dundee, UK), CCT (Leeds, UK) FRSM (London), MRCP (London), FRCP (Edin.)
Main Speciality: 
Medical Oncology

Other Medical Oncology,Palliative Care Physician Team Members

REQUEST AN APPOINTMENT